Barclays PLC Viking Therapeutics, Inc. Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 460,807 shares of VKTX stock, worth $18.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

460,807

Previous 231,200 99.31%

Holding current value

$18.3 Million

Previous $6.13 Million 92.08%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	BUY	$23.09 - $42.09 $5.3 Million - $9.66 Million	229,607 Added 99.31%	460,807 $11.8 Million
Q2 2025 Aug 13, 2025	SELL	$19.98 - $29.49 $4.29 Million - $6.33 Million	-214,495 Reduced 48.13%	231,200 $6.13 Million
Q1 2025 May 15, 2025	BUY	$24.15 - $42.89 $8.53 Million - $15.1 Million	353,139 Added 381.54%	445,695 $10.8 Million
Q4 2024 Feb 13, 2025	SELL	$38.28 - $78.03 $404,811 - $825,167	-10,575 Reduced 10.25%	92,556 $3.72 Million
Q3 2024 Nov 15, 2024	BUY	$49.84 - $70.47 $692,576 - $979,251	13,896 Added 15.57%	103,131 $6.53 Million

Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $2.81 Million - $4.76 Million	-59,368 Reduced 39.95%	89,235 $4.73 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $6.81 Million - $37 Million	-391,110 Reduced 72.47%	148,603 $12.2 Million
Q4 2023 Feb 15, 2024	BUY	$9.24 - $19.64 $164,388 - $349,415	17,791 Added 3.41%	539,713 $10 Million
Q3 2023 Nov 07, 2023	BUY	$10.92 - $16.0 $3.64 Million - $5.33 Million	332,913 Added 176.14%	521,922 $5.78 Million
Q2 2023 Aug 03, 2023	BUY	$14.84 - $24.79 $120,649 - $201,542	8,130 Added 4.49%	189,009 $3.07 Million
Q1 2023 May 04, 2023	BUY	$8.08 - $17.33 $1.15 Million - $2.47 Million	142,664 Added 373.32%	180,879 $3.01 Million
Q4 2022 Feb 13, 2023	BUY	$2.72 - $9.4 $92,969 - $321,292	34,180 Added 847.09%	38,215 $359,000
Q3 2022 Nov 03, 2022	BUY	$2.55 - $3.89 $10,286 - $15,692	4,034 Added 403400.0%	4,035 $11,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $24,115 - $36,001	-11,429 Reduced 99.99%	1 $0
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $214,806 - $349,417	-71,602 Reduced 86.23%	11,430 $35,000
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $250,768 - $366,340	54,515 Added 191.17%	83,032 $382,000
Q3 2021 Nov 09, 2021	BUY	$5.58 - $7.04 $106,036 - $133,781	19,003 Added 199.74%	28,517 $180,000
Q2 2021 Aug 13, 2021	SELL	$5.19 - $6.73 $375,148 - $486,464	-72,283 Reduced 88.37%	9,514 $57,000
Q1 2021 May 13, 2021	BUY	$5.74 - $9.67 $160,444 - $270,295	27,952 Added 51.91%	81,797 $517,000
Q4 2020 Feb 11, 2021	SELL	$5.3 - $6.71 $106,768 - $135,172	-20,145 Reduced 27.23%	53,845 $303,000
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $251,839 - $356,442	-43,951 Reduced 37.27%	73,990 $430,000
Q2 2020 Aug 12, 2020	BUY	$4.35 - $8.08 $178,502 - $331,562	41,035 Added 53.36%	117,941 $850,000
Q1 2020 May 13, 2020	SELL	$3.45 - $7.95 $7,890 - $18,181	-2,287 Reduced 2.89%	76,906 $359,000
Q4 2019 Feb 10, 2020	BUY	$6.38 - $8.73 $288,203 - $394,360	45,173 Added 132.78%	79,193 $635,000
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $186,733 - $245,177	-28,509 Reduced 45.59%	34,020 $234,000
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $347,174 - $481,156	45,264 Added 262.17%	62,529 $519,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $42,584 - $55,842	5,618 Added 48.24%	17,265 $172,000
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $981,507 - $2.22 Million	-137,082 Reduced 92.17%	11,647 $89,000
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $875,172 - $1.77 Million	-90,224 Reduced 37.76%	148,729 $2.59 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $870,206 - $2.86 Million	224,280 Added 1528.52%	238,953 $2.27 Million
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $53,380 - $90,006	12,988 Added 770.8%	14,673 $64,000
Q4 2017 Feb 14, 2018	BUY	$1.74 - $4.34 $2,931 - $7,312	1,685	1,685 $7,000

Others Institutions Holding VKTX

# of Institutions

433

Shares Held

66.6M

Call Options Held

7.21M

Put Options Held

3.87M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account